Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2023 1
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Dementia Risk in Parkinson Disease.
Gallagher J, Gochanour C, Caspell-Garcia C, Dobkin RD, Aarsland D, Alcalay RN, Barrett MJ, Chahine L, Chen-Plotkin AS, Coffey CS, Dahodwala N, Eberling JL, Espay AJ, Leverenz JB, Litvan I, Mamikonyan E, Morley J, Richard IH, Rosenthal L, Siderowf AD, Simuni T, York MK, Willis AW, Xie SX, Weintraub D; Parkinson's Progression Markers Initiative. Gallagher J, et al. Neurology. 2024 Sep 10;103(5):e209699. doi: 10.1212/WNL.0000000000209699. Epub 2024 Aug 7. Neurology. 2024. PMID: 39110916 Free PMC article.
Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial.
Jost ST, Aloui S, Evans J, Ashkan K, Sauerbier A, Rizos A, Petry-Schmelzer JN, Gronostay A, Fink GR, Visser-Vandewalle V, Antonini A, Silverdale M, Timmermann L, Martinez-Martin P, Chaudhuri KR, Dafsari HS; International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group and EUROPAR. Jost ST, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2352177. doi: 10.1001/jamanetworkopen.2023.52177. JAMA Netw Open. 2024. PMID: 38236600 Free PMC article. Clinical Trial.
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.
Dam T, Pagano G, Brumm MC, Gochanour C, Poston KL, Weintraub D, Chahine LM, Coffey C, Tanner CM, Kopil CM, Xiao Y, Chowdhury S, Concha-Marambio L, DiBiaso P, Foroud T, Frasier M, Jennings D, Kieburtz K, Merchant K, Mollenhauer B, Montine TJ, Nudelman K, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tolosa E, Siderowf A, Dunn B, Simuni T, Marek K; Parkinson’s Progression Markers Initiative. Dam T, et al. NPJ Parkinsons Dis. 2024 Sep 27;10(1):178. doi: 10.1038/s41531-024-00789-w. NPJ Parkinsons Dis. 2024. PMID: 39333167 Free PMC article.
Neuronal α-Synuclein Disease Stage Progression over 5 Years.
Simuni T, Gochanour C, Nair AR, Brumm MC, Coffey C, Poston KL, Chahine LM, Weintraub D, Tanner CM, Gonzalez-Latapi P, Kopil CM, Xiao Y, Chowdhury S, Dam T, Pagano G, Stephenson D, Siderowf A, Dunn B, Marek K; NSD Working Group the Parkinson's Progression Markers Initiative. Simuni T, et al. Mov Disord. 2025 Jul;40(7):1318-1330. doi: 10.1002/mds.30191. Epub 2025 Apr 30. Mov Disord. 2025. PMID: 40302527 Free PMC article.
Cognitive heterogeneity in Parkinson's disease: A mechanistic view.
Carceles-Cordon M, Weintraub D, Chen-Plotkin AS. Carceles-Cordon M, et al. Among authors: weintraub d. Neuron. 2023 May 17;111(10):1531-1546. doi: 10.1016/j.neuron.2023.03.021. Epub 2023 Apr 6. Neuron. 2023. PMID: 37028431 Free PMC article. Review.
LRRK2-associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization.
Chahine LM, Lafontant DE, Choi SH, Iwaki H, Blauwendraat C, Singleton AB, Brumm MC, Alcalay RN, Merchant K, Nudelman KNH, Dagher A, Vo A, Tao Q, Venuto CS, Kieburtz K, Poston KL, Bressman S, Gonzalez-Latapi P, Avants B, Coffey C, Jennings D, Tolosa E, Siderowf A, Marek K, Simuni T; Parkinson’s Progression Markers Initiative. Chahine LM, et al. Brain Commun. 2025 Mar 6;7(2):fcaf103. doi: 10.1093/braincomms/fcaf103. eCollection 2025. Brain Commun. 2025. PMID: 40114783 Free PMC article.
Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud TM, Toga AW, Tanner CM, Kieburtz KD, Mollenhauer B, Galasko D, Hutten S, Weintraub D, Siderowf AD, Marek K, Poston KL, Shaw LM; Parkinson's Progression Markers Initiative. Cousins KAQ, et al. Neurology. 2024 Feb;102(4):e208033. doi: 10.1212/WNL.0000000000208033. Epub 2024 Feb 2. Neurology. 2024. PMID: 38306599 Free PMC article.
Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases.
Kovacs GG, Robinson JL, Xie SX, Lee EB, Grossman M, Wolk DA, Irwin DJ, Weintraub D, Kim CF, Schuck T, Yousef A, Wagner ST, Suh E, Van Deerlin VM, Lee VM, Trojanowski JQ. Kovacs GG, et al. Among authors: weintraub d. J Neuropathol Exp Neurol. 2017 Apr 1;76(4):270-288. doi: 10.1093/jnen/nlx007. J Neuropathol Exp Neurol. 2017. PMID: 28340083 Free PMC article.
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC; NINDS NET-PD Investigators. Hauser RA, et al. Among authors: weintraub d. J Parkinsons Dis. 2017;7(1):117-127. doi: 10.3233/JPD-160965. J Parkinsons Dis. 2017. PMID: 27911341 Free article. Clinical Trial.